ABSTRACT
Beta 2 glycoprotein I (ß2GPI) is the major autoantigen in the antiphospholipid syndrome, an autoimmune disorder characterized by thrombotic and obstetric complications. The autoantibodies that target beta 2 glycoprotein I are pathogenic and contribute to disease pathogenesis. The ß2GPI molecule is composed of 5 domains that are numbered 1 through to 5. Autoantibodies bind mainly to domain 1 whereas the majority of the biological functions of the ß2GPI molecule in diverse processes such as apoptotic cell clearance, complement regulation, lipopolysaccharide clearance and anticoagulation have been localised to domain 5 and its unique biochemistry, reviewed in this article. The role of purified domain 5 peptide as a potential therapeutic agent in APS and ischemia reperfusion injury is discussed.
Subject(s)
Antiphospholipid Syndrome , Autoantibodies , beta 2-Glycoprotein I , Humans , beta 2-Glycoprotein I/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/drug therapy , Autoantibodies/immunology , Protein Domains , Animals , Autoantigens/immunology , Reperfusion Injury/immunologyABSTRACT
Little is known about the physiological role of beta-2-glycoprotein I (ß2GPI) despite it being the major auto-antigen in the antiphospholipid syndrome. A systematic study of the role of ß2GPI in thrombus formation in vivo has not been performed to date. Herein, we report that ß2GPI deficient (-/-) mice have enhanced thrombus formation compared to wild type (WT) mice in a laser-induced arteriole and venule model of thrombosis. Furthermore, neutrophil accumulation and elastase activity was enhanced in thrombi of ß2GPI -/- compared with WT mice. The antithrombotic function of ß2GPI is dependent on its fifth domain (domain V); intravenous administration of the ß2GPI domain deletion mutant lacking domain V (human recombinant domain I-IV) had no effect on platelet and fibrin thrombus size in ß2GPI -/- or WT mice. On the contrary, intravenous administration of human recombinant domain V significantly inhibited platelet and fibrin thrombus size in both ß2GPI -/- mice and WT mice. These findings reveal a major role for ß2GPI as a natural anticoagulant and implicate domain V of ß2GPI as a potential antithrombotic therapy.
Subject(s)
Antiphospholipid Syndrome , Thrombosis , beta 2-Glycoprotein I , Animals , Anticoagulants , Antiphospholipid Syndrome/drug therapy , Antiphospholipid Syndrome/genetics , Fibrinolytic Agents , Mice , Mice, Knockout , beta 2-Glycoprotein I/physiologyABSTRACT
OBJECTIVE: Atherosclerotic coronary artery disease is well recognised as an inflammatory disorder that is also influenced by oxidative stress. ß2-GPI (ß-2-glycoprotein-I) is a circulating plasma protein that undergoes post-translational modification and exists in free thiol as well as oxidized forms. The aim of this study was to assess the association between these 2 post-translational redox forms of ß2-GPI and atherosclerotic coronary artery disease. Approach and Results: Stable patients presenting for elective coronary angiography or CT coronary angiography were prospectively recruited. A separate group of patients after reperfused ST-segment-elevation myocardial infarction formed an acute coronary syndrome subgroup. All patients had collection of fasting serum and plasma for quantification of total and free thiol ß2-GPI. Coronary artery disease extent was quantified by the Syntax and Gensini scores. A total of 552 patients with stable disease and 44 with acute coronary syndrome were recruited. While total ß2-GPI was not associated with stable coronary artery disease, a higher free thiol ß2-GPI was associated with its presence and extent. This finding remained significant after correcting for confounding variables, and free thiol ß2-GPI was a better predictor of stable coronary artery disease than hs-CRP (high-sensitivity C-reactive protein). Paradoxically, there were lower levels of free thiol ß2-GPI after ST-segment-elevation myocardial infarction. CONCLUSIONS: Free thiol ß2-GPI is a predictor of coronary artery disease presence and extent in stable patients. Free thiol ß2-GPI was a better predictor than high-sensitivity C-reactive protein.
Subject(s)
Coronary Artery Disease/blood , Inflammation/blood , Oxidative Stress , beta 2-Glycoprotein I/blood , Acute Coronary Syndrome/blood , Acute Coronary Syndrome/diagnostic imaging , Aged , Biomarkers/blood , C-Reactive Protein/analysis , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Female , Heart Disease Risk Factors , Humans , Inflammation/diagnosis , Inflammation Mediators/blood , Lipids/blood , Male , Middle Aged , Oxidation-Reduction , Predictive Value of Tests , Prospective Studies , ST Elevation Myocardial Infarction/blood , ST Elevation Myocardial Infarction/diagnostic imagingABSTRACT
The constitutive heparin+ (HP) mast cells (MCs) in mice express mouse MC protease (mMCP)-5 and carboxypeptidase A (mMC-CPA). The amino acid sequence of mMCP-5 is most similar to that of human chymase-1, as are the nucleotide sequences of their genes and transcripts. Using a homologous recombination approach, a C57BL/6 mouse line was created that possessed a disrupted mMCP-5 gene. The resulting mice were fertile and had no obvious developmental abnormality. Lack of mMCP-5 protein did not alter the granulation of the IL-3/IL-9-dependent mMCP-2+ MCs in the jejunal mucosa of Trichinella spiralis-infected mice. In contrast, the constitutive HP+ MCs in the tongues of mMCP-5-null mice were poorly granulated and lacked mMC-CPA protein. Bone marrow-derived MCs were readily developed from the transgenic mice using IL-3. Although these MCs contained high levels of mMC-CPA mRNA, they also lacked the latter exopeptidase. mMCP-5 protein is therefore needed to target translated mMC-CPA to the secretory granule along with HP-containing serglycin proteoglycans. Alternately, mMCP-5 is needed to protect mMC-CPA from autolysis in the cell's granules. Fibronectin was identified as a target of mMCP-5, and the exocytosis of mMCP-5 from the MCs in the mouse's peritoneal cavity resulted in the expression of metalloproteinase protease-9, which has been implicated in arthritis. In support of the latter finding, experimental arthritis was markedly reduced in mMCP-5-null mice relative to wild-type mice in two disease models.
Subject(s)
Arthritis, Experimental/pathology , Chymases/adverse effects , Mast Cells/enzymology , Animals , Arthritis, Experimental/enzymology , Arthritis, Experimental/etiology , Carboxypeptidases A/analysis , Carboxypeptidases A/deficiency , Carboxypeptidases A/metabolism , Chymases/deficiency , Chymases/physiology , Humans , Mast Cells/metabolism , Mast Cells/pathology , Mice , Mice, Inbred C57BL , Secretory Vesicles/metabolismABSTRACT
The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understanding of the underlying complex pathogenesis of the APS. The first was the discovery that beta-2 glycoprotein-1 (ß2GPI) is the major auto antigen in APS. The second was the discovery in more recent years that ß2GPI contains allosteric disulphide bonds susceptible to posttranslational modification that may be involved in the development of autoantibodies in APS. The main allosteric disulphide bond in the fifth domain of ß2GPI can exist in two redox states: free thiol or oxidised. It is the conformational transformation of ß2GPI from its free thiol form to its more immunogenic oxidised form that exposes neo-epitopes on the first and fifth domains. The purpose of this review is to highlight the recent findings on the posttranslational forms of ß2GPI in the pathogenesis of APS. We suggest that novel assays quantitating the different redox forms of ß2GPI in plasma or serum may be used to supplement existing clinical and laboratory assays to more accurately stratify risk of thrombosis or miscarriage in APS patients.
ABSTRACT
Protease serine member S31 (Prss31)/transmembrane tryptase/tryptase-γ is a mast cell (MC)-restricted protease of unknown function that is retained on the outer leaflet of the plasma membrane when MCs are activated. We determined the nucleotide sequences of the Prss31 gene in different mouse strains and then used a Cre/loxP homologous recombination approach to create a novel Prss31(-/-) C57BL/6 mouse line. The resulting animals exhibited no obvious developmental abnormality, contained normal numbers of granulated MCs in their tissues, and did not compensate for their loss of the membrane tryptase by increasing their expression of other granule proteases. When Prss31-null MCs were activated with a calcium ionophore or by their high affinity IgE receptors, they degranulated in a pattern similar to that of WT MCs. Prss31-null mice had increased baseline airway reactivity to methacholine but markedly reduced experimental chronic obstructive pulmonary disease and colitis, thereby indicating both beneficial and adverse functional roles for the tryptase. In a cigarette smoke-induced model of chronic obstructive pulmonary disease, WT mice had more pulmonary macrophages, higher histopathology scores, and more fibrosis in their small airways than similarly treated Prss31-null mice. In a dextran sodium sulfate-induced acute colitis model, WT mice lost more weight, had higher histopathology scores, and contained more Cxcl-2 and IL-6 mRNA in their colons than similarly treated Prss31-null mice. The accumulated data raise the possibility that inhibitors of this membrane tryptase may provide additional therapeutic benefit in the treatment of humans with these MC-dependent inflammatory diseases.
Subject(s)
Colitis/enzymology , Lung/physiopathology , Mast Cells/enzymology , Membrane Proteins/immunology , Pulmonary Disease, Chronic Obstructive/enzymology , Tryptases/immunology , Animals , Colitis/genetics , Colitis/immunology , Colitis/physiopathology , Disease Models, Animal , Humans , Lung/enzymology , Lung/immunology , Male , Mast Cells/immunology , Membrane Proteins/genetics , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Knockout , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/immunology , Pulmonary Disease, Chronic Obstructive/physiopathology , Tryptases/geneticsABSTRACT
Patients with inflammatory bowel disease (IBD) have increased numbers of human tryptase-ß (hTryptase-ß)-positive mast cells (MCs) in the gastrointestinal tract. The amino acid sequence of mouse mast cell protease (mMCP)-6 is most similar to that of hTryptase-ß. We therefore hypothesized that this mMCP, or the related tryptase mMCP-7, might have a prominent proinflammatory role in experimental colitis. The dextran sodium sulfate (DSS) and trinitrobenzene sulfonic acid (TNBS) colitis models were used to evaluate the differences between C57BL/6 (B6) mouse lines that differ in their expression of mMCP-6 and mMCP-7 with regard to weight loss, colon histopathology, and endoscopy scores. Microarray analyses were performed, and confirmatory real-time PCR, ELISA, and/or immunohistochemical analyses were carried out on a number of differentially expressed cytokines, chemokines, and matrix metalloproteinases (MMPs). The mMCP-6-null mice that had been exposed to DSS had significantly less weight loss as well as significantly lower pathology and endoscopy scores than similarly treated mMCP-6-expressing mice. This difference in colitis severity was confirmed endoscopically in the TNBS-treated mice. Evaluation of the distal colon segments revealed that numerous proinflammatory cytokines, chemokines that preferentially attract neutrophils, and MMPs that participate in the remodeling of the ECM were all markedly increased in the colons of DSS-treated WT mice relative to untreated WT mice and DSS-treated mMCP-6-null mice. Collectively, our data show that mMCP-6 (but not mMCP-7) is an essential MC-restricted mediator in chemically induced colitis and that this tryptase acts upstream of many of the factors implicated in IBD.
Subject(s)
Inflammatory Bowel Diseases/immunology , Mast Cells/immunology , Tryptases/immunology , Animals , Chemokines/immunology , Colon/metabolism , Colon/pathology , Cytokines/immunology , Dextran Sulfate/toxicity , Enzyme-Linked Immunosorbent Assay , Immunohistochemistry , Inflammatory Bowel Diseases/chemically induced , Inflammatory Bowel Diseases/enzymology , Inflammatory Bowel Diseases/pathology , Mast Cells/metabolism , Matrix Metalloproteinases/immunology , Mice , Mice, Inbred C57BL , Microarray Analysis , Polymerase Chain Reaction , Trinitrobenzenesulfonic Acid/toxicity , Tryptases/metabolismABSTRACT
RasGRP4 (Ras guanine nucleotide-releasing protein-4) is an intracellular, calcium-regulated guanine nucleotide exchange factor and diacylglycerol/phorbol ester receptor expressed in mast cells (MCs) and their progenitors. To study the function of this signaling protein in inflammatory disorders, a homologous recombination approach was used to create a RasGRP4-null C57BL/6 mouse line. The resulting transgenic animals had normal numbers of MCs in their tissues that histochemically and morphologically resembled those in WT C57BL/6 mice. MCs could also be generated from RasGRP4-null mice by culturing their bone marrow cells in IL-3-enriched conditioned medium. Despite these data, the levels of the transcripts that encode the proinflammatory cytokines IL-1ß and TNF-α were reduced in phorbol 12-myristate 13-acetate-treated MCs developed from RasGRP4-null mice. Although inflammation was not diminished in a Dermatophagoides farinae-dependent model of allergic airway disease, dextran sodium sulfate-induced colitis was significantly reduced in RasGRP4-null mice relative to similarly treated WT mice. Furthermore, experimental arthritis could not be induced in RasGRP4-null mice that had received K/BxN mouse serum. The latter findings raise the possibility that the pharmacologic inactivation of this intracellular signaling protein might be an effective treatment for arthritis or inflammatory bowel disease.
Subject(s)
Arthritis, Experimental/metabolism , Inflammatory Bowel Diseases/metabolism , Signal Transduction , ras Guanine Nucleotide Exchange Factors/metabolism , Animals , Antigens, Dermatophagoides/toxicity , Arthritis, Experimental/genetics , Arthritis, Experimental/pathology , Arthritis, Experimental/therapy , Asthma/chemically induced , Asthma/genetics , Asthma/metabolism , Asthma/pathology , Carcinogens/pharmacology , Cells, Cultured , Cytokines/genetics , Cytokines/metabolism , Cytokines/pharmacology , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/pathology , Inflammatory Bowel Diseases/therapy , Mice , Mice, Knockout , Tetradecanoylphorbol Acetate/pharmacology , ras Guanine Nucleotide Exchange Factors/geneticsABSTRACT
Recent in vitro studies have shown that shear stress can cause platelet activation by agonist-independent pathways. However, no studies have assessed the extent of shear-induced platelet activation within human coronary arteries. We sampled blood from the coronary arteries proximal and distal to coronary lesions and from the coronary sinus in humans with stable coronary disease who were taking both aspirin and clopidogrel. A novel, computationally based technique for estimating shear stress from 3-dimensional coronary angiographic images of these arteries was developed, and the effect of stenosis severity and calculated shear stress on in vivo platelet and related leukocyte activation pathways were determined. We provide evidence of intracoronary up-regulation of platelet P-selectin, platelet-monocyte aggregation, and monocyte CD11b without platelet glycoprotein IIb-IIIa activation or soluble P-selectin up-regulation. This correlates with intracoronary stenosis severity and calculated shear stress and occurs despite the concurrent use of aspirin and clopidogrel. Our results show for the first time shear-related platelet and monocyte activation in human coronary arteries and suggest this as a potential therapeutic target that is resistant to conventional antiplatelet agents.
Subject(s)
Aspirin/pharmacology , Blood Platelets/drug effects , Coronary Artery Disease/metabolism , Coronary Stenosis/metabolism , Monocytes/drug effects , P-Selectin/metabolism , Platelet Aggregation/drug effects , Ticlopidine/analogs & derivatives , Aged , Blood Platelets/metabolism , CD11b Antigen/metabolism , Clopidogrel , Coronary Artery Disease/drug therapy , Coronary Artery Disease/pathology , Coronary Stenosis/drug therapy , Coronary Stenosis/pathology , Flow Cytometry , Humans , Leukocytes/drug effects , Leukocytes/pathology , Monocytes/metabolism , Monocytes/pathology , Platelet Aggregation Inhibitors/pharmacology , Ticlopidine/pharmacology , Up-RegulationABSTRACT
Factor XI (FXI), a disulfide-linked covalent homodimer, circulates in plasma, and upon activation initiates the intrinsic/consolidation phase of coagulation. We present evidence that disulfide bonds in FXI are reduced to free thiols by oxidoreductases thioredoxin-1 (TRX-1) and protein disulfide isomerase (PDI). We identified that Cys362-Cys482 and Cys118-Cys147 disulfide bonds are reduced by TRX-1. The activation of TRX-1-treated FXI by thrombin, FXIIa or FXIa was significantly increased compared to non-reduced FXI, indicating that the reduced factor is more efficiently activated than the oxidized protein. Using a novel ELISA system, we compared the amount of reduced FXI in antiphospholipid syndrome (APS) thrombosis patients with levels in healthy controls, and found that APS patients have higher levels of reduced FXI. This may have implication for understanding the contribution of FXI to APS thrombosis, and the predisposition to thrombosis in patients with elevated plasma levels of reduced FXI.
Subject(s)
Antiphospholipid Syndrome/blood , Factor XI/agonists , Protein Disulfide-Isomerases/blood , Thioredoxins/blood , Thrombosis/blood , Adult , Aged , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/enzymology , Blood Coagulation , Case-Control Studies , Cysteine/metabolism , Disulfides/chemistry , Enzyme-Linked Immunosorbent Assay , Factor XI/chemistry , Factor XI/metabolism , Factor XIIa/metabolism , Factor XIIa/pharmacology , Factor XIa/metabolism , Factor XIa/pharmacology , Female , Humans , Male , Middle Aged , Oxidation-Reduction , Thioredoxins/metabolism , Thioredoxins/pharmacology , Thrombin/metabolism , Thrombin/pharmacology , Thrombosis/complications , Thrombosis/enzymologyABSTRACT
ß2-Glycoprotein I (ß2GPI) is an evolutionary conserved, abundant circulating protein. Although its function remains uncertain, accumulated evidence points toward interactions with endothelial cells and components of the coagulation system, suggesting a regulatory role in vascular biology. Our group has shown that thioredoxin 1 (TRX-1) generates free thiols in ß2GPI, a process that may have a regulatory role in platelet adhesion. This report extends these studies and shows for the first time evidence of ß2GPI with free thiols in vivo in both multiple human and murine serum samples. To explore how the vascular surface may modulate the redox status of ß2GPI, unstimulated human endothelial cells and EAhy926 cells are shown to be capable of amplifying the effect of free thiol generation within ß2GPI. Multiple oxidoreductase enzymes, such as endoplasmic reticulum protein 46 (ERp 46) and TRX-1 reductase, in addition to protein disulfide isomerase are secreted on the surface of endothelial cells. Furthermore, one or more of these generated free thiols within ß2GPI are also shown to be nitrosylated. Finally, the functional significance of these findings is explored, by showing that free thiol-containing ß2GPI has a powerful effect in protecting endothelial cells and EAhy926 cells from oxidative stress-induced cell death.
Subject(s)
Endothelial Cells/metabolism , Oxidative Stress , Sulfhydryl Compounds/metabolism , beta 2-Glycoprotein I/metabolism , Adolescent , Adult , Aged , Animals , Blotting, Western , Cell Line , Cells, Cultured , Endothelial Cells/cytology , Endothelial Cells/drug effects , Female , Gene Expression Profiling , Humans , Hydrogen Peroxide/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Nitric Oxide/metabolism , Oxidants/pharmacology , Oxidation-Reduction/drug effects , Protein Disulfide-Isomerases/genetics , Protein Disulfide-Isomerases/metabolism , Sulfhydryl Compounds/blood , Thioredoxins/pharmacology , Young Adult , beta 2-Glycoprotein I/blood , beta 2-Glycoprotein I/geneticsABSTRACT
OBJECTIVE: Beta-2-glycoprotein I (ß2 GPI) constitutes the major autoantigen in the antiphospholipid syndrome (APS), a common acquired cause of arterial and venous thrombosis. We recently described the novel observation that ß2 GPI may exist in healthy individuals in a free thiol (biochemically reduced) form. The present study was undertaken to quantify the levels of total, reduced, and posttranslationally modified oxidized ß2 GPI in APS patients compared to various control groups. METHODS: In a retrospective multicenter analysis, the proportion of ß2 GPI with free thiols in serum from healthy volunteers was quantified. Assays for measurement of reduced as well as total circulating ß2 GPI were developed and tested in the following groups: APS (with thrombosis) (n=139), autoimmune disease with or without persistent antiphospholipid antibodies (aPL) but without APS (n=188), vascular thrombosis without APS or aPL (n=38), and healthy volunteers (n=91). RESULTS: Total ß2 GPI was significantly elevated in patients with APS (median 216.2 µg/ml [interquartile range 173.3-263.8]) as compared to healthy subjects (median 178.4 µg/ml [interquartile range 149.4-227.5] [P<0.0002]) or control patients with autoimmune disease or vascular thrombosis (both P<0.0001). The proportion of total ß2 GPI in an oxidized form (i.e., lacking free thiols) was significantly greater in the APS group than in each of the 3 control groups (all P<0.0001). CONCLUSION: This large retrospective multicenter study shows that posttranslational modification of ß2 GPI via thiol-exchange reactions is a highly specific phenomenon in the setting of APS thrombosis. Quantification of posttranslational modifications of ß2 GPI in conjunction with standard laboratory tests for APS may offer the potential to more accurately predict the risk of occurrence of a thrombotic event in the setting of APS.
Subject(s)
Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/blood , Thrombosis/etiology , beta 2-Glycoprotein I/blood , beta 2-Glycoprotein I/immunology , Adult , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/immunology , Female , Humans , Male , Middle Aged , Retrospective Studies , Thrombosis/blood , Thrombosis/immunologySubject(s)
Antiphospholipid Syndrome/etiology , Lupus Coagulation Inhibitor/physiology , Animals , Antiphospholipid Syndrome/physiopathology , Disease Models, Animal , Factor XI/physiology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Immunity, Innate/physiology , Mice , Oxidation-Reduction , Thromboplastin/physiology , Thrombosis/etiology , beta 2-Glycoprotein I/metabolismABSTRACT
This article discusses how we approach medical decision making in the treatment of the various facets of the antiphospholipid syndrome (APS), including secondary prophylaxis in the setting of venous and arterial thrombosis, as well as treatment for the prevention of recurrent miscarriages and fetal death. The role of primary thromboprophylaxis is also discussed in depth. Great emphasis is given to incorporating the most up-to-date and relevant evidence base both from the APS literature, and from large, recent, randomized controlled trials (RCTs) of primary and secondary thrombotic prophylaxis in the general population setting (ie, the population that has not been specifically investigated for APS).
Subject(s)
Antiphospholipid Syndrome/therapy , Abortion, Habitual/prevention & control , Female , Fetal Death/prevention & control , Humans , Male , Pregnancy , Randomized Controlled Trials as Topic , Thrombosis/prevention & controlABSTRACT
The antiphospholipid syndrome (APS) is an acquired thrombophilia, characterized by the occurrence of venous and arterial events. This article examines the laboratory and key clinical aspects of APS. Particular focus is given to anti-beta 2-glycoprotein I (beta(2)GPI) antibodies in view of their recent inclusion in the APS classification criteria. The clinical utility of using the beta(2)GPI enzyme-linked immunosorbent assay, in conjunction with the established lupus anticoagulant assays and cardiolipin enzyme-linked immunosorbent assay, for diagnosing and risk stratifying patients suspected of having APS is discussed. The relative importance of the various assays in diagnosing obstetric APS (early and late gestation miscarriages) is explored. The implications of recent epidemiologic findings for possibly understanding the underlying pathophysiologic mechanisms of obstetric APS are highlighted. Insights into which patients with obstetric APS may be at most risk of thrombotic complications are presented.
Subject(s)
Abortion, Spontaneous/blood , Abortion, Spontaneous/diagnosis , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/diagnosis , Lupus Coagulation Inhibitor/blood , Thrombophilia/blood , Thrombophilia/diagnosis , Abortion, Spontaneous/immunology , Antiphospholipid Syndrome/immunology , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Lupus Coagulation Inhibitor/immunology , Male , Pregnancy , Thrombophilia/immunology , beta 2-Glycoprotein I/immunologyABSTRACT
ß2-glycoprotein I (ß2GPI) is the major autoantigen in the antiphospholipid syndrome. The central importance of understanding ß2GPI physiology from the perspective of the rheumatologist is that it forms the foundation for understanding the pathophysiology underlying autoantibody generation, and the diverse mechanisms by which anti-ß2GPI antibodies in complex with ß2GPI may predispose an individual to the antiphospholipid syndrome clinical phenotype. This review examines some of the latest novel findings in this area.
Subject(s)
Antiphospholipid Syndrome/immunology , Autoantibodies/immunology , beta 2-Glycoprotein I/immunology , HumansABSTRACT
The anti-phospholipid syndrome (APS) is a prothrombotic autoimmune disorder characterized by either thrombosis or pregnancy complications in the setting of persistent anti-phospholipid antibodies (aPL). ßeta 2-glycoprotein I (ß2-GPI) is the major autoantigen in APS that binds anionic phospholipids as well as specific receptors on platelets and endothelial cells resulting in activation of prothrombotic pathways. ß2-GPI consists of 5 Domains that exist in a circular or linear form, with the latter occurring after binding to anionic phospholipids. ß2-GPI also undergoes dynamic posttranslational modification between oxidized and free thiol forms. The relationship between posttranslational modification and structural conformation is yet to be definitively clarified. Compared with controls, patients with the APS have higher levels of total ß2-GPI and lower levels of free thiol ß2-GPI. This raises the possibility of using quantification of ß2-GPI posttranslational modification as a redox biomarker in the management and diagnosis of the APS.
Subject(s)
Antiphospholipid Syndrome/physiopathology , Oxidative Stress , Protein Processing, Post-Translational , beta 2-Glycoprotein I/chemistry , beta 2-Glycoprotein I/metabolism , Animals , Glycolysis , Humans , Oxidation-ReductionABSTRACT
Complement Factor H (CFH) is an important inhibitor of the alternate complement pathway in Bruch's membrane (BM), located between the choriocapillaris and the retinal pigment epithelium. Furthermore dysfunction of its activity as occurs with certain polymorphisms is associated with an increased risk of age related macular degeneration (AMD). The retina is a site of high generation of reactive oxygen species (ROS) and dysfunction of redox homeostasis in this milieu also contributes to AMD pathogenesis. In this study we wanted to explore if CFH exists in distinct redox forms and whether these species have unique protective biological functions. CFH can be reduced by the naturally occurring thioredoxin -â¯1 in CFH domains 1-4, 17-20. We found a duality of function between the oxidised and reduced forms of CFH. The oxidised form was more efficient in binding to C3b and lipid peroxidation by-products that are known to accumulate in the retinae and activate the alternate complement pathway. Oxidised CFH enhances Factor I mediated cleavage of C3 and C3b whereas the reduced form loses this activity. In the setting of oxidative stress (hydrogen peroxide)-mediated death of human retinal pigment epithelial cells as can occur in AMD, the free thiol form of CFH offers a protective function compared to the oxidised form. We found for the first time using a novel ELISA system we have developed for free thiol CFH, that both redox forms of CFH are found in the human plasma. Furthermore there is a distinct ratio of these redox forms in plasma depending if an individual has early or late AMD, with individuals with early AMD having higher levels of the free thiol form compared to late AMD.
Subject(s)
Complement C3b/metabolism , Complement Factor I/metabolism , Macular Degeneration/genetics , Reactive Oxygen Species/metabolism , Aged , Bruch Membrane/immunology , Bruch Membrane/pathology , Case-Control Studies , Cell Line , Complement Activation/genetics , Complement C3b/genetics , Complement Factor H/genetics , Complement Factor H/metabolism , Complement Factor I/genetics , Complement Pathway, Alternative/genetics , Epithelial Cells/cytology , Epithelial Cells/immunology , Female , Gene Expression , Humans , Lipid Peroxidation , Macular Degeneration/immunology , Macular Degeneration/pathology , Male , Oxidation-Reduction , Protein Binding , Proteolysis , Reactive Oxygen Species/immunology , Retinal Pigment Epithelium/immunology , Retinal Pigment Epithelium/pathology , Time FactorsABSTRACT
Nitrosative stress has been implicated in the pathogenesis of age related macular degeneration (AMD). Tyrosine nitration is a unique type of post translational modification that occurs in the setting of inflammation and nitrosative stress. To date, the significance and functional implications of tyrosine nitration of complement factor H (CFH), a key complement regulator in the eye has not been explored, and is examined in this study in the context of AMD pathogenesis.Sections of eyes from deceased individuals with AMD (n = 5) demonstrated the presence of immunoreactive nitrotyrosine CFH. We purified nitrated CFH from retinae from 2 AMD patients. Mass spectrometry of CFH isolated from AMD eyes revealed nitrated residues in domains critical for binding to heparan sulphate glycosaminoglycans (GAGs), lipid peroxidation by-products and complement (C) 3b.Functional studies revealed that nitrated CFH did not bind to lipid peroxidation products, nor to the GAG of perlecan nor to C3b. There was loss of cofactor activity for Factor I mediated cleavage of C3b with nitrated CFH compared to non-nitrated CFH. CFH inhibits, but nitrated CFH significantly potentiates, the secretion of the pro-inflammatory and angiogenic cytokine IL-8 from monocytes that have been stimulated with lipid peroxidation by-products. AMD patients (n = 30) and controls (n = 30) were used to measure plasma nitrated CFH using a novel ELISA. AMD patients had significantly elevated nitrated CFH levels compared to controls (p = 0.0117). These findings strongly suggest that nitrated CFH contributes to AMD progression, and is a target for therapeutic intervention.